ADR Therapeutics Commences Joint Research with Medical Arc on Canine Joint and Inflammatory Diseases Using 'Neocella'
ADR Therapeutics, a subsidiary of ADR120S, has commenced research on the application of its next-gen… · 2026-05-22
ADR Therapeutics, a subsidiary of ADR120S, has commenced research on the application of its next-gen… · 2026-05-22
ADR Therapeutics has announced a joint research agreement with Northern Farm to study the applicatio… · 2026-05-19
ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Me… · 2026-05-15
ADR Therapeutics, a subsidiary of ADR120S, has entered into a joint research agreement with Tokyo Me… · 2026-05-15
ADR120S Inc. announced that its development product "CrymEX" has been confirmed to meet extracellula… · 2026-04-03
ADR120S Inc. announced that its development product "CrymEX" has been confirmed to meet extracellula… · 2026-04-03
ADR120S Inc. announced that its development product "CrymEX" has been confirmed to meet extracellula… · 2026-04-03